IL17A and cancer: Additionally, by stimulating cancer cells to release inflammatory chemokines (CCL2 or CCL20), IL-17A-producing cells can enhance CD1a+ DC infiltration of the TME, which is correlated with favorable OS of patients with ESCC (18).